Single-enantiomer MDMA can deliver a different therapeutic and side-effect profile. Videra Health is the multimodal observation platform that captures the behavioral differences in trial data — turning 'we removed the bad enantiomer' into a measured, defensible claim.
See how we'd observe AM1002Single-enantiomer MDMA for PTSD, designed to retain therapeutic benefit while reducing the side effects of racemic MDMA.
AM1002 is single-enantiomer MDMA — designed to retain the therapeutic benefit of MDMA-assisted therapy while reducing the side effects that come from the unwanted enantiomer.
The therapeutic case is grounded in 20 years of MDMA research. The differentiation case lives in the trial data: which symptoms improve faster, which side effects truly diminish, and what happens to therapeutic alliance under a different subjective profile.
Comparative behavioral data — vocal patterns, facial affect, somatic response, linguistic content — surfaces the differences between AM1002 and racemic MDMA at the session level. MADRS at Day 28 cannot.
The story matters to the FDA, to payers, and to clinicians who watched the Lykos approval cycle.
Building the case for single-enantiomer MDMA in PTSD.
'We removed the bad enantiomer' is a chemistry claim. The four observation gaps below convert it into clinical evidence.
How AM1002's session feels different from racemic MDMA's session is a question PRO scales were not designed to answer. Vocal affect, facial expressivity, and linguistic patterns can.
Anxiety, sympathetic activation, post-session fatigue — all measurable in continuous behavioral observation. The data Arcadia needs to substantiate the differentiation case.
How patient-therapist alliance evolves with AM1002 vs racemic MDMA is observable in session interaction patterns — and informs both label claims and clinician training.
The answer lives in head-to-head behavioral data, captured under directly comparable conditions. Videra delivers the framework.
Our platform pairs in-clinic AI hardware with multimodal behavioral analytics and a custom algorithm engine, already proven in TDScreen and Check on Mom. Here's how each maps to AM1002.
A clinical-grade camera and directional audio rig that drops into any AM1002 site in minutes. Same framing, same fidelity, same conditions as MDMA comparison sessions. The basis for any 'AM1002 vs racemic' claim.
Multimodal analysis of voice, video, and language across AM1002 and comparator sessions. The behavioral differentiation data that turns chemistry into clinical evidence.
For AM1002, a proprietary single-enantiomer differentiation framework — capturing the specific behavioral and physiological signatures that distinguish AM1002 from racemic MDMA.
AI-powered tardive dyskinesia screening built on the AIMS standard. AUC 0.89 vs. trained raters, peer-reviewed in J Clin Psychiatry.
Conversational AI + video screener for postpartum depression. Used in real homes, on real devices, validated against clinical frameworks.
Multimodal AI model trained on AM1002 vs racemic MDMA data, surfacing the behavioral, somatic, and linguistic signatures that distinguish the single-enantiomer profile.
Your differentiation strategy, mapped to Videra capabilities in production.
Videra's network isn't our customer base. It's the living dataset that powers every algorithm we build. For Arcadia Medicine, that means real clinical depth and peer-reviewed validation.
We'd welcome a 30-minute session to walk Arcadia Medicine through a tailored, protocol-by-protocol proposal for AM1002's PTSD program.